No therapy is currently approved to treat HIV-associated fat redistribution. There is a need for effective treatments.

The purpose of this study is designed to confirm the findings of an earlier Serostim™ study, which indicated that it can significantly reduce truncal fat accumulations, elevated non-HDL cholesterol and related cardio-vascular risk parameters.

 

 

This thirty-six week study is designed for HIV-infected volunteers who have evidence of excess abdominal fat desposits who have been taking antiretroviral medications for at least 30 days prior to study entry.

This study will compare the use of Serostim™ with placebo; volunteers will be randomly assigned to one of three groups.

 

• HIV-positive adult 18 years or older
• Documentation of HIV infection
• Evidence of excess abdominal adipose (fat) deposition
• Taking antiretroviral medications for 30 days prior to study entry

Ongoing; closed to enrollment.
--

This ad was reviewed and approved by the AIDS ReSearch Alliance Institutional Review Board in June, 2004.